Expert Details Immunotherapy Developments in Lung Cancer – OncLive
OncLive |
Expert Details Immunotherapy Developments in Lung Cancer
OncLive “If there's benefit in immunotherapy administration in the arm with [PD-L1] negative populations, even if the relative benefit is smaller, that may be a good rationale for use in those contexts if the patients who respond have durable responses—that … |
